國家衛生研究院 NHRI:Item 3990099045/15473
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 909718      線上人數 : 823
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/15473


    題名: Pulmonary delivery of remdesivir and dexamethasone encapsulated nanostructured lipid carriers for enhanced inflammatory suppression in lung
    作者: Chen, CW;Chang, CP;Wen, YS;Kuo, CH;Lin, SW;Tsai, JC;Shyong, YJ
    貢獻者: Institute of Biotechnology and Pharmaceutical Research
    摘要: The COVID-19 pandemic, originating from the first reported outbreak in China in January 2020, has arguably become the most formidable global health challenge of the 21st century. Characterized by its rapid spread, the virus has profoundly disrupted lives globally, primarily infecting the cells in the respiratory system. Post-infection, it induces intracellular virus replication, causing cell death and lung inflammation. Severe cases may be complicated by lung fibrosis and fatal cytokine storms, emphasizing the need for efficacious treatment strategies that address both viral infection and inflammatory response [1]. The COVID-19 treatment guidelines issued by the US National Institutes of Health in 2022 underscored the importance of both antiviral and immune modulation therapy, with varying recommendations based on the severity of the disease. For patients with mild symptoms, not requiring hospitalization or supplemental oxygen, therapies like Paxlovid and Remdesivir were advocated to expedite recovery [2]. On the contrary, patients with moderate to severe disease necessitating hospitalization were recommended a combined approach of antiviral and immune-modulator therapy. Key agents in these guidelines include Remdesivir, an antiviral drug, and Dexamethasone, an immune-modulator, illustrating the dual importance of combating the virus while controlling the immune response [2]. As end of 2022, Remdesivir remains the only FDA approved therapeutic for COVID-19 treatment. This antiviral medication is a prodrug that readily crosses cell membranes and transforms into its active form, GS-443902. Once inside an infected cell, GS-443902 disrupts the function of viral RNA polymerase, halting the replication of the viral RNA [3, 4]. However, owing to its low oral bioavailability and hydrophobic nature, it must be dissolved using sulfobutylether-beta-cyclodextrin (SBCD) and administered via intravenous (IV) infusion for at least 2 h [2,5]. This extensive administration period significantly hampers the convenience of Remdesivir’s usage. Furthermore, systemic exposure to the drug and SBCD may cause liver and kidney complications, amongst other adverse reactions. Clinical data indicate that the incidence of adverse effects after 5–10 days of treatment ranges from 70 % to 74 %, including severe adverse effects in 21 %–34 % of cases, necessitating premature cessation of treatment [6]. Previous clinical trials have also highlighted that following IV infusion, the concentration of Remdesivir in the lungs maybe insufficient to effectively inhibit viral replication [7]. The rapid metabolism of Remdesivir to GS-441524, a form unable to penetrate cell membranes, during systemic circulation may further limit its therapeutic efficacy in lungs [8].
    日期: 2023-12
    關聯: Journal of Drug Delivery Science and Technology. 2023 Dec;90:Article number 105144.
    Link to: http://dx.doi.org/10.1016/j.jddst.2023.105144
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1773-2247&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001111134400001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85175793776
    顯示於類別:[張竣評] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    SCP85175793776.pdf3915KbAdobe PDF108檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋